Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Collins

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal MelanomaRichard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
Innate Immunity|September 19, 2013
Activation of liver X receptor suppresses the production of the IL-12 family of cytokines by blocking nuclear translocation of NF-κBp50Mary Canavan, Ciara McCarthy, Nadia Ben Larbi, et al.
Histopathology|July 23, 2022
Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR)Stephen B Fox, Fluer Webster, Chih-Jung Chen, et al.
Nature Communications|March 11, 2025
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancerEsra Güç, Agatha Treveil, Emma Leach, et al.
Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.
Immunotherapy Advances|December 11, 2024
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAMEAna R Ribeiro, Camille Britton-Rivet, Laura Collins, et al.
BMJ Open|July 1, 2024
Helping ourselves, helping others: the Young Women's Breast Cancer Study (YWS) - a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and youngerShoshana M Rosenberg, Yue Zheng, Kathryn Ruddy, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Journal of Clinical Apheresis|October 18, 2024
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis DataAndrew D Johnson, Zbigniew M Szczepiorkowski, Rasheed A Balogun, et al.
Academic Pediatrics|August 11, 2023
Adapting Behavioral Treatments for Primary Care Using a Theory-Based Framework: The Case of Adolescent Eating DisordersJocelyn Lebow, Leslie Sim, Sarah Redmond, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2022
Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal MelanomaRichard D Carvajal, Paul Nathan, Joseph J Sacco, et al.
Innate Immunity|September 19, 2013
Activation of liver X receptor suppresses the production of the IL-12 family of cytokines by blocking nuclear translocation of NF-κBp50Mary Canavan, Ciara McCarthy, Nadia Ben Larbi, et al.
Histopathology|July 23, 2022
Dataset for pathology reporting of ductal carcinoma in situ, variants of lobular carcinoma in situ and low-grade lesions: recommendations from the International Collaboration on Cancer Reporting (ICCR)Stephen B Fox, Fluer Webster, Chih-Jung Chen, et al.
Nature Communications|March 11, 2025
Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancerEsra Güç, Agatha Treveil, Emma Leach, et al.
Cell Reports. Medicine|April 16, 2025
Evolution of the tumor immune landscape during treatment with tebentafusp, a T cell receptor-CD3 bispecificJoseph J Sacco, Peter Kirk, Emma Leach, et al.
Immunotherapy Advances|December 11, 2024
High-affinity T cell receptor ImmTAC® bispecific efficiently redirects T cells to kill tumor cells expressing the cancer-testis antigen PRAMEAna R Ribeiro, Camille Britton-Rivet, Laura Collins, et al.
BMJ Open|July 1, 2024
Helping ourselves, helping others: the Young Women's Breast Cancer Study (YWS) - a multisite prospective cohort study to advance the understanding of breast cancer diagnosed in women aged 40 years and youngerShoshana M Rosenberg, Yue Zheng, Kathryn Ruddy, et al.
Journal for Immunotherapy of Cancer|June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanomaJoseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Journal of Clinical Apheresis|October 18, 2024
Development of a Uniform Apheresis Case Report Form for Standardized Collection of Apheresis DataAndrew D Johnson, Zbigniew M Szczepiorkowski, Rasheed A Balogun, et al.
Academic Pediatrics|August 11, 2023
Adapting Behavioral Treatments for Primary Care Using a Theory-Based Framework: The Case of Adolescent Eating DisordersJocelyn Lebow, Leslie Sim, Sarah Redmond, et al.
Pageof 6